42% buyers of institutions opening or closing positions this quarter
6 more exits than new buyers, ownership rose 5.82 percentage points vs the prior quarter, and 3 well-known fund managers in the top 25.
42% buyers of institutions opening or closing positions this quarter
81.2% institutional ownership
Peapod Lane Capital portfolio allocation
Institutional ownership vs Biotechnology peers
No Form 4 insider transactions on file
Latest positioning in PLRX across 13F flow, ownership shift, marquee holders, and holder-count growth.
Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in PLRX held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | TANG CAPITAL MANAGEMENT LLC | 6.1M | $7.7M | 0.0% | 9.921% | 0.39% |
| 2 | CITADEL ADVISORS LLC | 3.3M | $4.1M | +20.5% | 5.270% | 0.00% |
| 3 | Blue Owl Capital Holdings LP | 3.0M | $3.7M | 0.0% | 4.795% | 1.01% |
| 4 | ADAR1 Capital Management, LLC | 2.6M | $3.3M | +3402.0% | 4.175% | 0.19% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | $3.0M | β | 3.784% | 0.00% |
| 6 | TWO SIGMA INVESTMENTS, LP | 2.3M | $2.8M | +136.3% | 3.639% | 0.00% |
| 7 | Monaco Asset Management SAM | 1.9M | $2.4M | 0.0% | 3.131% | 0.45% |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 1.9M | $2.3M | +77.2% | 2.992% | 0.00% |
| 9 | Prosight Management, LP | 1.7M | $2.1M | +7.2% | 2.693% | 0.34% |
| 10 | Woodline Partners LP | 1.7M | $2.1M | -17.7% | 2.692% | 0.01% |
| 11 | BML Capital Management, LLC | 1.5M | $1.9M | 0.0% | 2.497% | 1.25% |
| 12 | Peapod Lane Capital LLC | 1.3M | $1.6M | +45.4% | 2.081% | 1.30% |
| 13 | MILLENNIUM MANAGEMENT LLC | 1.2M | $1.5M | +188.8% | 1.906% | 0.00% |
| 14 | BlackRock, Inc. | 1.1M | $1.4M | +2.2% | 1.771% | 0.00% |
| 15 | UBS Group AG | 1.1M | $1.3M | -0.4% | 1.709% | 0.00% |
| 16 | MARSHALL WACE, LLP | 996K | $1.3M | -7.8% | 1.608% | 0.00% |
| 17 | Eversept Partners, LP | 891K | $1.1M | +5.9% | 1.440% | 0.06% |
| 18 | Redmile Group, LLC | 772K | $973K | -52.2% | 1.247% | 0.06% |
| 19 | JACOBS LEVY EQUITY MANAGEMENT, INC | 719K | $905K | +29.0% | 1.160% | 0.00% |
| 20 | GOLDMAN SACHS GROUP INC | 597K | $752K | +115.6% | 0.964% | 0.00% |
| 21 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 554K | $698K | +72.2% | 0.894% | 0.01% |
| 22 | Connor, Clark & Lunn Investment Management Ltd. | 517K | $652K | +39.1% | 0.836% | 0.00% |
| 23 | MORGAN STANLEY | 506K | $637K | -7.9% | 0.817% | 0.00% |
| 24 | XTX Topco Ltd | 501K | $631K | -8.1% | 0.809% | 0.01% |
| 25 | DAFNA Capital Management LLC | 487K | $614K | β | 0.787% | 0.14% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in PLRX β a direct measure of their conviction.
Filings activity in PLRX during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new PLRX position in Q1 2026
Institutions that fully closed their PLRX position in Q1 2026
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 89 | 6.3% | 81.20% | +5.82 pp | $57M | +7.7% |
| Q4 2025 | 95 | 2.1% | 75.38% | 24.51 pp | $53M | 25% |
| Q3 2025 | 97 | 14% | 99.89% | +18.52 pp | $70M | +23% |
| Q2 2025 | 113 | 19% | 81.37% | 26.27 pp | $57M | 24% |
| Q1 2025 | 140 | 13% | 107.64% | 92.35 pp | $75M | 90% |
| Q4 2024 | 160 | +6.7% | 199.99% | +0.00 pp | $774M | +18% |
| Q3 2024 | 150 | +4.9% | 199.99% | +0.00 pp | $657M | +6.0% |
| Q2 2024 | 143 | β | 199.99% | β | $620M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
No recent Form 4 insider transactions on file for PLRX.
Quick answers to the most common questions about buying PLRX stock.
Based on Q1 2026 13F filings, institutional ownership of Pliant Therapeutics, Inc. stands at 81.2%, held across 89 reporting institutions.
TANG CAPITAL MANAGEMENT LLC is the largest reported institutional holder of PLRX, with approximately 6,143,132 shares worth $0.01B as of Q1 2026.
Yes β 3 widely-followed marquee investors appear among the top 25 institutional holders of PLRX, including CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC.
Our composite Smart Money Score for PLRX is 65 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
16 institutions opened new positions in PLRX during Q1 2026, while 22 fully exited. 53 added to existing positions and 18 trimmed.
PLRX institutional ownership rose by 5.82 percentage points quarter-over-quarter, with a net change of -6 holders.
The top 10 institutions account for 59.2% of all reported 13F value in PLRX, and the top 25 account for 87.3%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.